Download PDF
Thromb Haemost 2010; 103(03): 489-495
DOI: 10.1160/TH09-04-0247
Theme Issue Article
Schattauer GmbH

What is the appropriate approach to prevention of thromboembolism in heart failure?

Ronald S. Freudenberger
1   Lehigh Valley Health Network, Allentown, Pennsylvania, USA
,
Matthew M. Schumaecker
1   Lehigh Valley Health Network, Allentown, Pennsylvania, USA
,
Shunichi Homma
2   Columbia University, Medicine, New York, New York, USA
› Author Affiliations
Further Information

Publication History

Received: 17 April 2009

Accepted after major revision: 27 October 2009

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

Many studies suggest a higher incidence of thromboembolic syndromes such as stroke, peripheral arterial thrombosis and pulmonary embolism in patients with heart failure (HF), particularly those with left ventricular systolic dysfunction. As a result, some clinicians have chosen to treat patients with HF with anticoagulants as primary prevention against thromboembolic events. However, this practice is not well-supported by scientific data. Retrospective analyses of large HF trials have yielded contradictory results and randomised trials designed to specifically address this question have been under-populated and under-powered. As a result, there is no general consensus among professional societies in either recommending or advising against anticoagulants in HF. We hope that ongoing clinical trials, WARCEF in particular, will yield results that will guide clinicians in deciding for or against routine use of anticoagulants in HF.

Keywords

Heart - stroke/prevention - thrombosis - cardiology
 

  • References

  • 1 Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medicine. Frankfurt: Meidinger Sohn & Co; 1856: 219-732.
    Google Scholar
  • 2 Kapur NK, Deming CB, Kapur S. et al. Hemodynamic modulation of endocardial thromboresistance. Circulation 2007; 115: 67-75.
    PubMedGoogle Scholar
  • 3 Alehagen U, Dahlstrom U, Lindahl TL. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004; 92: 1250-1258.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Jafri SM, Ozawa T, Mammen E. et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993; 14: 205-212.
    CrossrefPubMedGoogle Scholar
  • 5 Yamamoto K, Ikeda U, Furuhashi K. et al. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 25: 1634-1640.
    CrossrefPubMedGoogle Scholar
  • 6 Sbarouni E, Bradshaw A, Andreotti F. et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127: 607-612.
    CrossrefPubMedGoogle Scholar
  • 7 Molvarec A, Rigo Jr. J, Boze T. et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009; 101: 305-311.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Chong AY, Freestone B, Patel J. et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006; 97: 671-675.
    CrossrefPubMedGoogle Scholar
  • 9 Fischer D, Rossa S, Landmesser U. et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalisation, cardiac transplantation, or death. Eur Heart J 2005; 26: 65-69.
    CrossrefPubMedGoogle Scholar
  • 10 Mechtcheriakova D, Wlachos A, Holzmuller H. et al. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999; 93: 3811-3823.
    PubMedGoogle Scholar
  • 11 Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995; 15: 612-621.
    CrossrefPubMedGoogle Scholar
  • 12 Jug B, Vene N, Salobir BG. et al. Prognostic impact of haemostatic derangements in chronic heart failure. Thromb Haemost 2009; 102: 314-320.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4: 361-368.
    CrossrefPubMedGoogle Scholar
  • 14 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
    CrossrefPubMedGoogle Scholar
  • 15 Munger M. Tissue factor expression in stage C heart failure (TFHF). University of Utah; 2009.
    PubMedGoogle Scholar
  • 16 Lowe GD, Rumley A, Whincup PH. et al. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med 2002; 2: 429-439.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
    CrossrefPubMedGoogle Scholar
  • 18 Meschia JF, Brott TG, Chukwudelunzu FE. et al. Verifying the stroke-free phenotype by structured telephone interview. Stroke 2000; 31: 1076-1080.
    CrossrefPubMedGoogle Scholar
  • 19 Isnard R, Komajda M. Thromboembolism in heart failure, old ideas and new challenges. Eur J Heart Fail 2001; 3: 265-269.
    CrossrefPubMedGoogle Scholar
  • 20 Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 1983; 250: 2942-2946.
    CrossrefPubMedGoogle Scholar
  • 21 Freudenberger RS, Hellkamp A, Lee K. et al. The Incidence of Thromboembolism in Patients With NYHA Class II and III Heart Failure: An Analysis From the Sudden Cardiac Death in Heart FailureTrial (SCD-HeFT). Circulation 2006; 115: 2637-2641.
    PubMedGoogle Scholar
  • 22 Dunkman WB, Johnson GR, Carson PE. et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl. 06) VI94-101.
    CrossrefPubMedGoogle Scholar
  • 23 Effects of enalapril on mortality in severe congestive heart failure.. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. NEnglJMed 1987; 316: 1429-1435.
    CrossrefPubMedGoogle Scholar
  • 24 Dries DL, Rosenberg YD, Waclawiw MA. et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. JAmCollCardiol 1997; 29: 1074-1080.
    PubMedGoogle Scholar
  • 25 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
    CrossrefPubMedGoogle Scholar
  • 26 Loh E, Sutton MS, Wun CC. et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. NEnglJ Med 1997; 336: 251-257.
    CrossrefPubMedGoogle Scholar
  • 27 Hays AG, Sacco RL, Rundek T. et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006; 37: 1715-1719.
    CrossrefPubMedGoogle Scholar
  • 28 Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 54: 288-294.
    CrossrefPubMedGoogle Scholar
  • 29 Katz SD, Marantz PR, Biasucci L. et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993; 126: 141-146.
    CrossrefPubMedGoogle Scholar
  • 30 Gruhn N, Larsen FS, Boesgaard S. et al. Cerebral blood flow in patients with chronic heart failure before and after heart transplantation. Stroke 2001; 32: 2530-2533.
    CrossrefPubMedGoogle Scholar
  • 31 Choi BR, Kim JS, Yang YJ. et al. Factors associated with decreased cerebral blood flow in congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2006; 97: 1365-1369.
    CrossrefPubMedGoogle Scholar
  • 32 Busing KA, Schulte-Sasse C, Fluchter S. et al. Cerebral Infarction: Incidence and Risk Factors after Diagnostic and Interventional Cardiac Catheterization--Prospective Evaluation at Diffusion-weighted MR Imaging. Radiology 2005; 235: 177-183.
    CrossrefPubMedGoogle Scholar
  • 33 Friday G, Sutter F, Curtin A. et al. Brain Magnetic Resonance Imaging Abnormalities following Off-Pump Cardiac Surgery. Heart SurgForum 2005; 8: E105-E109.
    PubMedGoogle Scholar
  • 34 Giele JL, Witkamp TD, Mali WP. et al. Silent brain infarcts in patients with manifest vascular disease. Stroke 2004; 35: 742-746.
    CrossrefPubMedGoogle Scholar
  • 35 Echemann M, Alla F, Briancon S. et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Fail 2002; 4: 647-654.
    CrossrefPubMedGoogle Scholar
  • 36 Cleland JG, Findlay I, Jafri S. et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148: 157-164.
    CrossrefPubMedGoogle Scholar
  • 37 Massie BM, Collins JF, Ammon SE. et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-1624.
    CrossrefPubMedGoogle Scholar
  • 38 Cokkinos DV, Haralabopoulos GC, Kostis JB. et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006; 8: 428-432.
    CrossrefPubMedGoogle Scholar
  • 39 Pullicino P, Thompson JL, Barton B. et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006; 12: 39-46.
    CrossrefPubMedGoogle Scholar
  • 40 Hart RG, Halperin JL, Pearce LA. et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138: 831-838.
    CrossrefPubMedGoogle Scholar
  • 41 Parkash R, Wee V, Gardner MJ. et al. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol 2007; 23: 457-461.
    CrossrefPubMedGoogle Scholar
  • 42 Hylek EM, Evans-Molina C, Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
    CrossrefPubMedGoogle Scholar
  • 43 Albers GW, Amarenco P, Easton JD. et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 483S-512S.
    CrossrefPubMedGoogle Scholar
  • 44 Swedberg K, Cleland J, Dargie H. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140.
    CrossrefPubMedGoogle Scholar
  • 45 Hirsh J, Fuster V, Ansell J. et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-1711.
    CrossrefPubMedGoogle Scholar
  • 46 Hacke W, Kaste M, Olsen TS. et al. European Stroke Initiative: recommendations for stroke management. Organisation of stroke care. J Neurol 2000; 247: 732-748.
    PubMedGoogle Scholar
  • 47 Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006; 12: 10-38.
    CrossrefPubMedGoogle Scholar